1.1Lipid carrier for RNA
The lipid particle encloses messenger RNA during extracellular transit. Cells take up the particle by endocytosis, and RNA that reaches the cytosol serves as a template for translation.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The lipid particle encloses messenger RNA during extracellular transit. Cells take up the particle by endocytosis, and RNA that reaches the cytosol serves as a template for translation.
The RNA forms a closed loop with no free 5′ or 3′ end. An internal initiation sequence recruits ribosomes in the cytosol and supports translation of the coding region.
A spinal needle introduces the protein into the lumbar subarachnoid space. Cerebrospinal fluid circulation distributes the dissolved protein along fluid spaces around the spinal cord and brain.
The channel inserts into cellular membranes during synthesis and intracellular sorting directs it to the lysosomal membrane. Its activity alters ion movement across that membrane in cells that express it.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A transparent head model holds a replaceable gel block with a marked target. A blunt training cannula delivers colored water into the block while a side camera records the fluid front. Trainees inspect the recording to see where the cannula tip stops and whether dye travels back along the insertion track.
An aqueous suspension of fluorescent polystyrene beads replaces the viral suspension in a sealed bench fixture. A syringe and a length of clear tubing connect to a transparent collection chamber. A fluorescence microscope images the chamber contents and the rinsed tubing separately to show where beads collect.
A transparent test cartridge contains three straight channels with widths of 1, 2, and 4 mm and a common depth of 1 mm. Each channel has a separate inlet and outlet and receives the same volume of colored water. An overhead camera records the fluid front against a millimeter scale so its travel distance can be compared across the three channels.
A benchtop ultrasound imaging system connects to a linear array probe mounted above a gel phantom. The phantom contains an embedded target and a blunt training cannula that enters through a guide attached to the fixture. The display shows the cannula tip and target in the same imaging plane as the operator advances the cannula.
A fixed camera records a transparent gel coupon on a uniformly lit stage. Software subtracts a baseline image taken before dye enters and applies an intensity threshold to identify the colored region in each frame. A scale marker in the same image plane converts the region's pixel count to square millimeters for a time series.
A closed water circuit with removable tubing joints sits above a drip tray mounted on a load cell. A data logger records tray mass and timestamps at one-second intervals during each run. Software subtracts the starting mass and flags a sustained increase as a leak.
The capsid protein has the amino acid sequence identified by SEQ ID NO: 1. Peptide mapping compares peptides measured from the capsid preparation with the expected fragments of that sequence.
A polyadenylation signal lies downstream of the coding sequence. Cellular RNA processing machinery cleaves the transcript downstream of the signal and adds a polyadenosine tail.
The transgene encodes full-length human progranulin with its native amino-terminal signal peptide. The signal peptide directs the growing protein into the endoplasmic reticulum, and the secretory pathway releases the processed protein from the cell.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins.A · US 2012/0009268 A1 · abstract
In related embodiments, disclosed herein is an infectious recombinant AAV comprising a variant AAV capsid protein at least 90% identical to the sequence set forth as SEQ ID NO:42 and a heterologous nucleic acid comprising a sequence encoding a VEGF inhibitor, preferably a VEGFa inhibitor, and a pharmaceutical composition comprising the same.B · US 2020/0282077 A1 · ¶ 20
In embodiments of the invention the rAAV vector genome comprises at least one TR sequence (e.g., AAV TR sequence), optionally two TRs (e.g., two AAV TRs), which typically will be at the 5′ and 3′ ends of the vector genome and flank the heterologous nucleic acid, but need not be contiguous thereto.A · US 2012/0009268 A1 · ¶ 73
If an AAV virion comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild-type AAV genome, e.g., a transgene to be delivered to a target cell, an RNAi agent or CRISPR agent to be delivered to a target cell, etc.), it is typically referred to as a “recombinant AAV (rAAV) virion” or an “rAAV viral particle.” In general, the heterologous polynucleotide is flanked by at least one, and generally by two, AAV inverted terminal repeat sequences (ITRs).B · US 2020/0282077 A1 · ¶ 67
An empty cell means only that no passage was reproduced there.
However, such regulatory components do not preclude sequestration of AAV vector genomes in off-target organs following systemic administration.A · US 2012/0009268 A1 · ¶ 4
Thus, the invention provides an array of synthetic viral vectors displaying a range of transduction profiles that are suitable for different in vitro and in vivo applications.A · US 2012/0009268 A1 · ¶ 7
However, these AAVs (including AAV2) have not been reported to be effective at transducing the deeper cell types of the retina when delivered via intravitreal administration.B · US 2020/0282077 A1 · ¶ 5
Accordingly, there is a need in the art for new AAV variants with superior transduction capabilities that will provide for more effective gene-based delivery to the cells of the retina for the treatment of ocular disease.B · US 2020/0282077 A1 · ¶ 5
patent.fyi, US 2026/0355347 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355347/, SHA-256 3d4599d460362b8133dea566892eab1fbe2e61e545a17b1b10e3a0db12ecb14e